Study of Everolimus in the Treament of Neurocognitive Problems in Tuberous Sclerosis

August 7, 2013

Tuberous sclerosis (TSC) is a genetic disorder characterized by the development of benign tumors in many organs, including skin, kidneys and brain. Brain involvement is a major concern and can present as seizures, memory problems, and behavioral disorders.

The TRON study

The TRON study is a randomized, double blind, placebo-controlled study of RAD001 (Everolimus) in the treatment oneurocognitive problems in tuberous sclerosis). The study is open for recruitment of patients with the condition.


If you have tuberous sclerosis and fulfill the following criteria, we would be pleased to hear from you

  • age: 16-60 years
  • are able and willing to do some memory and thinking tests
  • have no epilepsy or reasonably controlled epilepsy

If you are interested in taking part, a member of the study team will speak to you by phone as an initial check to see whether you are likely to be eligible.


Read more here. 

Stay Connected

Sign up for updates straight to your inbox.